EODData

MEMBERSHIP REGISTER LOG IN

OTCBB, NVSEF: Novartis Ag

14 Oct 2025
LAST:

131.5

CHANGE:
 1.48		OPEN:
131.5		HIGH:
131.5		ASK:
0.0		VOLUME:
100
CHG(%):
1.13		PREV:
130.0		LOW:
131.5		BID:
0.0		 

CHART

RECENT END OF DAY PRICES

DateOpenHighLowCloseVolume
14 Oct 25131.5131.5131.5131.5100
09 Oct 25130.0130.0130.0130.0100
08 Oct 25127.1137.4127.1127.1200.5K
07 Oct 25131.0131.0127.9128.81.3K
06 Oct 25132.4132.4132.4132.4300
03 Oct 25128.0128.0128.0128.0160.1K
01 Oct 25128.8128.8125.8125.8140.9K
30 Sep 25123.5123.5123.5123.5100
29 Sep 25124.6124.6118.0124.680.8K
26 Sep 25124.0124.0124.0124.0100

COMPANY PROFILE

Name:Novartis Ag
About:Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart failure with reduced ejection fraction (HFrEF); Cosentyx to treat plaque psoriasis, pso riatic arthritis, ankylosing spondylitis, and nonradiographic axial spondy loarthritis; Kisqali, a selective oral cyclin dependent inhibitor of kinases 4 and 6 (CDK4/6); Promacta/Revolade to treat immune thrombocytopenia (ITP), thrombocytopenia, and patients with severe aplastic anemia (SAA); Tafinlar+Mekinist, an oral combination therapy to treat patients with certain types of cancers; and Jakavi for the treatment of myelofibrosis, polycythemia vera, and acute or chronic graftversushost disease (GvHD). It also provides Tasigna to treat philadelphia chromosomepositive chronic myeloid leukemia in the chronic and/or accelerated phase; Xolair for the treatment of allergic asthma and nasal polyps or severe chronic rhinosi nusitis with nasal polyps; Ilaris to treat fever syndromes, Still's disease, and acute gouty arthritis; Pluvicto to treat prostatespecific membrane anti genpositive metastatic castrationresistant prostate cancer; Sandostatin SC and Sandostatin LAR to treat acromegaly carcinoid tumors and other types of functional gastro intestinal and pancreatic neuroendocrine tumors; Zolgensma for the treatment of genetic root cause of spinal muscular atrophy; Lucentis; Leqvio to reduce LDL cholesterol; Lutathera; Scemblix; and Fabhalta. The company focuses on therapeutic areas, such as cardiovascular, renal and metabolic, immunology, neuroscience, oncology, and hematology. It has a license and collaboration agreement with Alnylam Pharmaceuticals, Inc. to develop, manufacture, and commercialize Leqvio (inclisiran), a therapy to reduce LDL cholesterol. Novartis AG was incorporated in 1996 and is headquartered in Basel, Switzerland.
Sector:Healthcare
Address:Lichtstrasse 35, Basel, Switzerland, 4056
Website:https://www.novartis.com
CUSIP:66987V109
CIK:0001114448
ISIN:CH0012005267
FIGI:BBG000KSBX82
LEI:5493007HIVTX6SY6XD66

API SERVICE  NEW

Have you tried our new API Service yet?

For more information, visit our API page.

You can get your ApiKey over HERE.

If you're ready to get going, then jump over to:
https://api.eoddata.com

SYMBOL HISTORY

   Add to Watchlist

DOWNLOAD DATA

Download stock quote history quickly and easily in a variety of formats to suit your needs.

  Download

FUNDAMENTALS

Trailing P/E:18.65 
Forward P/E:13.64 
DivYield:0.03 
Div/Share:3.86 
Price to Book:5.80 
Price to Sales:4.66 
EBITDA:23.552B 
Shares:1.936B 
Market Cap:254.517B 

TECHNICAL INDICATORS

MA5:129.951.2%
MA10:127.573.1%
MA20:126.154.2%
MA50:121.648.1%
MA100:116.2613.1%
MA200:111.2618.2%
STO9:57.28
STO14:62.31
RSI14:64.11 
WPR14:-8.73 
MTM14:9.09
ROC14:0.07 
ATR:3.27 
Week High:137.394.5%
Week Low:127.103.4%
Month High:137.394.5%
Month Low:118.0218.2%
Volatility:39.65